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ABSTRACT
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an autoimmune condition that commonly
causes kidney impairment and can be fatal. The key participation of B-lymphocytes as ANCA producers and neutrophils as
target of these antibodies is widely described as the mechanism of endothelial damage in this disease. There has been a
rising interest in the role of T-lymphocytes in AAV in recent years. Evidence is strong from animal models, and T-
lymphocytes can be found infiltrating kidney tissue and other tissue sites in AAV patients. Furthermore, the different
subsets of T-lymphocytes are also key players in the aberrant immune response observed in AAV. Polarization towards a
predominant Th1 and Th17 response in the acute phase of the disease has been described, along with a decline in the
number of T-regulatory lymphocytes, which, in turn, show functional impairment. Interactions between different T-cell
subsets, and between T-cells and neutrophils and B-cells, also enhance the inflammatory response, constituting a complex
network. Novel therapies targeting T-cell immunity are emerging in this scenario and may constitute an interesting
alternative to conventional therapy in selected patients. This review aims to summarize the available evidence regarding
T-cell imbalances and functional impairment, especially focusing on renal involvement of AAV.
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INTRODUCTION
Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vas-
culitis (AAV) affects small and medium-sized vessels [1]. Renal
involvement is frequent. Although ANCA trigger an immune re-
action, glomerular damage is pauci-immune, given the scarce
deposition of immune complexes [2]. Several lines of evidence
for the implication of T-lymphocytes in AAV exist. Firstly, biop-
sies from AAV patients show the presence of extensive T-cell
infiltrates in different renal compartments. Secondly, studies in
animal models show attenuation of histological lesions in the
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absence of different T-cell subsets, and a 20-amino acid region
(MPO409–428) was identified as an immunodominant T-cell
epitope by Ooi et al. in a murine model of myeloperoxidase
(MPO)-induced glomerulonephritis [3]. Finally, amelioration of
the disease after T-cell-directed therapies suggests a role for
T-cells in the pathogenesis [4].
Here, we aim to review the recent evidence regarding the im-
balance of T-cells, their related functional impairment and their




CD8þ T-lymphocytes, classically named cytotoxic, are impor-
tant in the defence against intracellular pathogens and cancer.
After recognition of peptides presented by major histocompati-
bility complex (MHC) class I, they cause cellular death by
cytotoxicity via induction of apoptosis and secretion of the pro-
inflammatory cytokines tumour necrosis factor-alpha (TNF-a)
and interferon-gamma (IFN-c) [5]. Available data from preclini-
cal models, and also in human AAV, point to CD8þ T-cells as
playing a direct role in tissue damage in AAV, at least in part, to-
gether with other innate immunity cells [6].
In a murine model of anti-MPO glomerulonephritis, Chang
et al. showed that CD8þ T-cell blockade diminished the extent
of histological lesions and renal impairment. They also proved
that CD8þ T-cells selectively caused glomerulonephritis when
transferred to mice with kidney-planted MPO antigen [7].
In human AAV, the proportion of activated CD8þ T-cells is
elevated, according to various authors [6, 8, 9]. McKinney et al.
explored blood CD8þ T-cell gene expression profile in AAV.
They found that the higher expression of a particular subgroup
of genes related to T-cell survival and expansion of memory
CD8þ T-cells was strongly associated with a shorter time to re-
lapse after induction of remission treatment. Those upregulated
genes were specifically implicated in interleukin (IL)-7 and
T-cell receptor (TCR) signalling pathways. If these findings are
validated in prospective studies and can be adapted into a clini-
cally viable test, then this could help to identify those patients
with a greater propensity to relapse, thus enabling therapy cus-
tomization [10]. Kidder et al., in a T-cell marker validation study
including 38 renal biopsies from AAV patients, found an in-
creased number of CD8þ T-cells in the periglomerular area and
interstitium in kidneys with crescentic histology, and a signifi-
cant correlation between the number of CD8þ T-cells and the
glomerular filtration rate. Despite the low number of
T-lymphocytes infiltrating the glomeruli, CD8þ T-cells predo-
minated over CD4þ T-cells [11].
Mechanistically, the importance of the CD8þ T-cell subset
may reside in their capability to activate polymorphonuclear
(PMN) cells [6]. PMN cell activation is a key event in the patho-
genesis of AAV that leads to exposure of proteinase 3 and MPO
on their surface, allowing their recognition by ANCA [1]. IFN-c
secreted by CD8þ T-cells during the acute phase of AAV is a po-
tent activator of PMN cells, thus explaining the contribution of
the CD8þ T-cell subset to disease pathogenesis.
Helper T-lymphocytes
CD4þ T-cells, classically named T-helper cells, orchestrate the
adaptive immune response. They activate B-cells, macrophages
and cytotoxic T-cells via a wide range of cytokines that, in turn,
constitute the signature of every T-helper cell subset [12]. As
ANCA production is T-cell-dependent, B-cells require stimula-
tion from previously activated T-helper lymphocytes to produce
antibodies. After CD4þ T-cells recognize antigens exposed by
antigen-presenting cells and become activated, they are able to
activate, in turn, B-cells that bind the same antigen on their
B-cell receptor [13] (Figure 1). B-cell activation leads to prolifera-
tion, isotype switch and antibody secretion.
In the MPO-induced glomerulonephritis murine model,
CD4þ T-cell depletion diminished the extent of the disease [14].
In vitro proliferation and ANCA production [15] of peripheral
blood mononuclear cells (PBMCs) from AAV patients in re-
sponse to MPO stimulation disappeared after CD4þ T-cell deple-
tion. The beneficial effects of the use of anti-thymocyte globulin
(ATG) in patients with AAV for induction of remission also con-
stitute proof of concept [16].
Next we will further discuss the reported evidence of imbal-
ances and functional disturbances in the different subsets of T-
helper cells in AAV. Controversial results have been found in
this setting, with a changing predominance of the different sub-
sets, depending on the AAV phenotype and disease activity.
Th1/Th2 subset imbalance
Th1 cells release IL-2, IFN-c and TNF-a after activation, trigger
macrophages and cytotoxic T-cells, as part of the intracellular
pathogen defence, and stimulate immunoglobulin G (IgG) class
switch by B-cells [10]. On the other hand, Th2 cells release IL-4,
IL-5, IL-10 and IL-13 after activation and stimulate B-cells, con-
stituting the main defence against extracellular pathogens.
Available data point to a predominance of the Th1 immune
response in AAV, especially during the acute phase. Masutani et
al. found a higher peripheral Th1/Th2 ratio in AAV acute
patients compared with controls, that significantly decreased in
remission, and a higher tissue expression of IFN-c in kidney bi-
opsies [17]. Abdulahad et al. described a predominance of the
Th1 subset during the acute and remission phases of the dis-
ease, but in particular they observed a polarization towards Th2
response in remission in the memory cell population [18]. Popa
et al. stimulated PBMCs from AAV remission patients with pro-
teinase 3 and found a predominance of Th2 ILs in the superna-
tant, with very low IFN-c levels [19]. Szczeklik et al. also found
higher peripheral Th2 cell counts during remission in AAV
patients [20], in line with the higher plasma levels of CCL22 pro-
duced by this subset, as observed by Eriksson et al. [21].
Th1 polarization in the acute phase is related to an altered
co-stimulation pattern. CD28 co-stimulation promotes the dif-
ferentiation of naı̈ve T-cells to a Th2 profile, whereas the ab-
sence of this co-stimulatory signal and an increased B7 (CD80/
86) expression, both features present in AAV, as will be later dis-
cussed, should lead to differentiation to a Th1 profile [22].
Interestingly, IgG3 is the strongest immunoglobulin subclass in-
ducing neutrophil activation, and the IgG switch to IgG3 mainly
depends on Th1 induction [23]. On the other hand, authors hy-
pothesize that polarization to a Th2 response in the remission
phase represents an imbalance recovery [20] or a poorer suscep-
tibility to immunosuppressive therapy of this T-cell subset [24].
Additionally, differences in Th1/Th2 imbalance have been
described, depending on the clinical phenotype or extent of the
disease. Müller et al. suggested that in granulomatosis with pol-
yangiitis (GPA), a predominant Th1 response is found in
patients with localized disease, based on the findings of higher
IFN-c expression both in nasal biopsies and in PBMCs in
patients with localized disease compared with those with
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generalized disease [25]. The authors hypothesized that in gen-
eralized GPA, a delayed-type hypersensitivity response related
to Th2 is of greater importance [26], even though these findings
have not been reproduced in other GPA cohorts [18]. Regarding
eosinophilic GPA (EGPA), predominance of the Th2 response
has been documented, which may indicate underlying aetiopa-
thogenic differences with a major role of allergic response [27].
In summary, the bulk of the evidence points to a predomi-
nance of Th1 response, which probably enhances neutrophil ac-
tivation that occurs early in the development of the disease.
Meanwhile, in the remission phase, this polarization reverts,
such that Th2 is the main participating T-cell subset.
Th17 subset
The Th17 T-helper subset is involved in defence against extra-
cellular bacteria and fungi, and is implicated in autoimmune
diseases [28]. Th17 cells express the transcription factor RORct3
and produce IL-17A–F, mainly IL-17A. IL-23 is required by the
Th17 subset to expand and mature [29]. In turn, Th17 cells are
inhibited by Th1 and Th2 cytokines.
Various authors proved the role of IL-17-producing cells in a
murine model of crescentic glomerulonephritis. IL-17 induces
the renal expression of C-X-C Motif Chemokine Ligand 5
(CXCL5) by the tubular epithelium that is responsible for neutro-
phil attraction [30]. Gan et al. compared the histological lesions
and kidney function parameters in IL-17 and IL-17 receptor
knock-out mice with wild-type specimens in an MPO-induced
glomerulonephritis model. Knock-out animals showed less
histological damage and better renal function compared with
wild-type mice, suggesting a pivotal role of Th17 cells in the
disease [31].
Given that neutrophils have a prominent role in AAV, the
Th17 cell subset has also been a focus of attention in recent
years because of the interplay between these two cell types.
Expansion of the Th17 subset has been described in the setting
of the acute phase of AAV, with a decline in early remission.
Nogueira et al. demonstrated significantly higher levels of se-
rum IL-17A in a cohort of 28 AAV acute patients and 65 AAV
convalescent patients compared with healthy controls, with se-
rum IL-23 levels following the same pattern [32]. Szczeklik et al.
found higher proportions of circulating Th17 cells in AAV
patients compared with healthy controls, by flow cytometry
[20]. Specificity of this Th17 response against proteinase 3 was
evaluated by Abdulahad et al., who found a higher percentage of
activated Th17 cells after stimulation with proteinase 3 in a co-
hort of 29 AAV patients in remission compared with healthy
controls, as well as higher levels of IL-17 in the supernatant of
stimulated AAV lymphocytes [33]. Additional results from
Nogueira et al. were in agreement with these studies, describing
higher percentages of IL-17-producing cells after stimulation
with proteinase 3 or MPO, using the ELISPOT method, in a group
of 17 AAV patients compared with healthy controls [32]. By con-
trast, other authors did not find evidence of this expanded Th17
response in AAV [20, 21, 34]. It may be hypothesized this is due
to a high susceptibility of this cellular subset to steroids, as a
FIGURE 1: Proposed role for T-lymphocytes in AAV. The neutrophil is the key cell in AAV. After neutrophil priming and surface exposure of proteinase 3 or MPO, ANCA
produced by B-lymphocytes are able to bind to their target antigen. ANCA binding fully activates neutrophils and causes degranulation. Endothelial damage and fur-
ther inflammation are promoted by substances contained inside neutrophilic granules. Th1 response also results directly in cytotoxicity. In addition, Th1 response
causes neutrophil priming and IgG3 class switch in B-cells, which constitutes the main antibody class found in AAV. Th2 response is less prominent in the acute phase
of AAV and promotes antibody formation. Th17 stimulates further neutrophil recruitment to sites of tissue damage, thus promoting and amplifying the inflammatory
response. Cross-talk between Th17 and neutrophils results in a feedback loop, with neutrophils, in turn, stimulating Th17 infiltration. Depending on the cytokine mi-
lieu, Th17 cells can acquire either a Th1- or a Th2-like phenotype, thus exhibiting high plasticity. Persistent exposure to antigen promotes the expansion of the T-
helper lymphocyte memory subset. Aberrant expression of NKG2D in a subgroup of these effector memory T-cells has been described, conferring NK-cell-like cytotox-
icity against endothelial cells, thus contributing to tissue damage. Treg inhibition of the immune response is impaired during the acute phase of AAV and tends to re-
cover during remission, thus allowing an uncontrolled auto-inflammatory response.
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possible explanation [35], or due to the variety of cytokines in
the IL-17 family. For instance, Krohn et al. found no differences
in serum IL-17A levels from 70 AAV patients compared with
healthy controls, but interestingly they found a significant
elevation in IL-17C levels [36].
Whether the Th17 subset is the main source of production of
IL-17 in AAV is also controversial. Velden et al. demonstrated
the presence of IL-17 in an immunohistochemistry study in-
cluding 22 AAV diagnostic kidney biopsies. Co-localization of
the cytokine with other cellular markers identified neutrophils
as the main source of IL-17, followed by mast cells and lastly by
Th17 lymphocytes [37].
Under certain circumstances and in certain cytokine milieus,
Th17 cells undergo epigenetic modifications, thus showing high
plasticity and a capability of altering their phenotype and func-
tion. Under stimulation by IL-12 or IL-1b (produced by antigen-
presenting cells in the presence of danger molecules), Th17 cells
express IFN-c and acquire a Th1-like phenotype. If stimulated
by IL-4, they convert into cells with a Th2-like phenotype. Along
the same line, under IL-1b and IL-6 stimulation, T-regulatory
lymphocytes (Tregs) (see T-regulatory subset section) can ac-
quire a Th17-like phenotype and produce IL-17 [38]. However, it
seems that in immune-mediated kidney diseases, Th17 cells
display minimum plasticity compared with other autoimmune
conditions [39]. In AAV, the proportion of Th1-like Th17 cells is
higher in the acute phase of the disease or in the remission
phase of the disease with no treatment compared with healthy
controls, but the significance of this subset needs to be further
studied [40].
Knowledge of the existence of the Th17 subset is relatively
recent. The role of Th17 cells in the development of AAV and
their interaction with other immune cells remain to be fully elu-
cidated, although knock-out murine models prove that this role
certainly exists. Linking with the pathogenesis of AAV, what is
clear at the moment is that by induction of a variety of chemo-
kines, the Th17 subset enhances the recruitment of neutrophils
to the inflammation site and contributes to organ damage in
AAV. This cross-talk is reciprocal, and neutrophils also are able
to induce chemotaxis of Th17 cells, which makes this cellular
axis even more interesting as a possible target in the treatment
of AAV, similar to other inflammatory conditions [41].
T-regulatory subset
Tregs inhibit T-effector cells and are responsible for antigen-
specific peripheral tolerance and autoimmunity prevention [5].
Tregs are defined as CD4þCD8–CD25 (IL-2R)þFOXP3þ T-cells.
FOXP3 is a transcription factor indispensable for Treg develop-
ment and function. The role of Treg disturbances in the patho-
genesis of crescentic glomerulonephritis has been proven in
animal models. Tan et al. reduced the Treg population in a mu-
rine model of MPO-induced glomerulonephritis by the adminis-
tration of an anti-CD25 antibody. They found a higher
proportion of MPO-specific Th1 and Th17 cells, higher kidney
functional impairment and more severe histological lesions
compared with vehicle-treated animals [42]. Along the same
line, Paust et al. generated mice lacking CXCR3 specifically in
Tregs, which is crucial for Tregs to migrate to inflammation
sites. These mice showed enhanced kidney impairment and
more severe histological lesions with lower Treg infiltration
compared with wild-type mice, after induction of nephrotoxic
nephritis [43].
Various authors described a higher proportion of Tregs in
patients during the acute phase of AAV, with a decrease when
remission was reached [34, 44]. In addition, Morgan et al. found
that patients with a higher Treg count at presentation entered
into earlier remission compared with those with a lower Treg
count, as well as a negative correlation between Tregs and
disease relapse rate, suggesting that higher numbers of Tregs
suppress AAV activity [45]. Opposite results have been reported
by other authors, who observed a depletion of T regs in the
acute phase and progressive expansion in the remission phase,
together with a negative correlation between Tregs and activity
markers [20]. At tissue level, Yoshimura et al. correlated a lower
FOXP3 expression by immunostaining of AAV renal biopsies
with the requirement for maintenance dialysis, suggesting that
lower Treg infiltration translates into higher disease activity
[46].
Various proliferation studies proved diminished suppressor
function of Tregs in AAV patients compared with healthy con-
trols [34, 45, 47], although with occasional increase in the
proliferation of T-effector cells after interaction with Tregs [47].
Morgan et al. found that Treg function was impaired, particu-
larly in patients who remained persistently ANCA-positive over
time compared with those who became ANCA-negative [45],
consistent with a higher degree of activity of the disease. The
mechanistical explanation for Treg impairment lies in the
higher resistance of T-effector cells to Tregs and Treg hypofunc-
tionality, associated with the expression of a FOXP3 isoform
lacking exon 2, which contains a crucial domain for its suppres-
sive properties [44].
In summary, probably both population imbalances and func-
tional impairment of Tregs in AAV lead to an uncontrolled in-
flammatory state that relieves and stabilizes in the remission
phase of the disease. Controversy regarding the number and
functionality of Tregs in AAV is, in part, due to the changing gat-
ing strategies used to identify those cells, the heterogeneity of
the disease stages and the differences in treatment of the
patients included in the studies [34], so conclusions should be
drawn cautiously.
Memory T subset
Memory T-cells are a subset of T-cells that previously encoun-
tered their specific antigens, and thus they are also called
‘antigen-experienced T-cells’. They have the capability of
quickly expanding in number and activating after re-exposure
to the antigen. They are CD4þ or CD8þ, and usually express
CD45RO [48].
Of interest is the finding of an increased population of effec-
tor memory T-cells with a parallel decrease in the naı̈ve T-cell
population, reflecting hyperactivation in the setting of continu-
ous exposure to auto-antigens in AAV [33]. During the remission
phase of the disease, persistent expansion of CD4þ T-cells with
an effector memory phenotype has been described, together
with a decrement in the amount of circulating CD4þ naı̈ve cells.
Strikingly, during a disease flare-up, a decrease in CD4þ effector
memory T-cells has been observed [49, 50]. In line with this
finding, Abdulahad et al. hypothesized that this phenomenon is
due to migration of those cells to sites of tissue damage. They
observed the presence of infiltrating CD4þ effector memory
T-cells in renal biopsies and also in urinary sediments from
patients who had experienced a disease flare-up, which disap-
peared when remission was reached again [51].
In summary, regarding T-cell subsets, virtually all have been
found to be expanded. Various authors have reported an expan-
sion of Th1 and Th17 effector memory T-cells in GPA and micro-
scopic polyangiitis, and an expansion of Th2 and Th17 effector
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memory T-cells in patients with EGPA [52]. Aberrant expression
of Natural Killer Group 2D (NKG2D) in a subgroup of these effec-
tor memory T-cells has been described, conferring a natural
killer (NK) cell-like cytotoxicity against endothelial cells, and
thus contributing to tissue damage [53].
Follicular T-helper subset
Follicular T-helper (Tfh) cells are required for the development
of the germinal centre where B-lymphocyte antigenic affinity
undergoes maturation. The role of these cells is being investi-
gated in autoimmunity and seems to be more prominent in dis-
eases with a higher participation of autoantibodies. Altered Tfh
cells may lead to the generation of aberrant autoantibodies and
the formation of ectopic follicles [54].
Abdulahad et al. identified increased circulating Tfh cells,
identified as BCL6þ IL-21-producing cells, compared with healthy
controls. The percentage of these cells was significantly higher
in ANCA-positive, compared with ANCA-negative, patients.
Moreover, IL-21 enhanced spontaneous ANCA production in cul-
tures of PBMCs from ANCA-positive patients compared with
ANCA-negative patients [55]. This way, the expanded population
of circulating Tfh cells may be collaborating in the production of
ANCA autoantibodies, which constitutes the trigger for the initia-
tion of an inflammatory response in AAV.
ALTERATIONS IN T-LYMPHOCYTE
ACTIVATION IN AAV
T-lymphocytes express TCR. Ninety-five per cent of lympho-
cytes express ab-chain TCR, and 5% express a variant cd-chain
TCR [5]. The first signal for T-cell activation consists of TCR rec-
ognition of peptides presented by MHC molecules. The second
signal for activation of effector T-cells consists of the binding of
CD28 to B7. By contrast, CTLA-4 binding to B7 inhibits this
activation.
Differential expression of TCR genes in the variable domain
of the a and b chains has been found in AAV patients [56], with
an increased expression of the V2.1 gene in the b chain com-
pared with healthy controls [57]. T-cells carrying cd-chain TCR
are involved in innate host defence and can produce IL-17. The
role of these IL-17-producing, cd-chain TCR-expressing T-cells
in AAV has been addressed in murine models [58, 59]. In c and d
chain knock-out murine models, structural and glomerular in-
jury is attenuated. Limited evidence exists on the role of the cd
T-cell subset, but interestingly the presence of infiltrating cd T-
cells in biopsies from AAV patients has been observed, in con-
trast to healthy controls [60], and the authors hypothesized this
could lead to disturbances in antigen recognition. In the case of
IL-17-producing, cd-chain TCR-expressing T-cells, it may be re-
lated to the neutrophil attraction function of this IL.
CD28 expression decreases in AAV patients, thus resulting
in resistance to anergy [6, 61]. A negative correlation of the per-
centage of CD28þ cells with disease activity has been estab-
lished [61]. CD4þCD28 T-cell infiltrate is present in the nasal
tissue of AAV patients with upper respiratory tract involvement
[62]. CTLA-4 is overexpressed in AAV patients compared with
healthy controls [63], and certain CTLA-4 polymorphisms have
been correlated with a higher susceptibility to the development
of AAV [64]. Whether it also preserves inhibitory functions
remains to be elucidated [65].
By contrast, IL-2 binding to IL-2R is the second signal for acti-
vation of Tregs [5] and is critical to their survival and functional-
ity. Wilde et al. showed a lower expression of the b subunit of IL-
2R (CD122) compared with Tregs from healthy controls [66].
Altogether, altered co-stimulation of T-cells in AAV promotes
effector T-cell anergy and causes impaired activation of Tregs,
which, in turn, contributes to a more pronounced pro-inflam-
matory state.
T-LYMPHOCYTES AS A THERAPEUTICAL
TARGET IN AAV
T-lymphocytes constitute an interesting therapeutic target,
given their prominent role in the pathogenesis of the disease.
Reported therapies along this line are directed to abolish the
T-cell response, either by cell depletion or by targeting their
cytokines. Classical therapies such as use of cyclophosphamide
or corticosteroids affect T-lymphocytes. Cyclophosphamide
causes decreased B- and T-helper lymphocyte counts, and con-
sequently an increased CD4/CD8 ratio that can persist for years
[67]. Naı̈ve T-lymphocytes are especially sensitive to cyclophos-
phamide [68]. Similarly, prednisone decreases the circulating
T-cell count, particularly CD4þ T-cells, with a minor effect on
B-cell count [69].
Lymphocyte-depleting antibodies
The humanized anti-CD52 monoclonal antibody alemtuzumab
selectively depletes lymphocytes and has been shown to be ef-
fective in other systemic vasculitides such as Behçet’s disease
[70]. Incomplete recovery of the CD4þ population and predomi-
nance of Tregs occur in remission and may benefit disease con-
trol [71]. Walsh et al. treated 71 patients with refractory or
relapsing AAV with alemtuzumab and found it useful to achieve
remission with a lower relapse rate [72].
ATG is a mix of polyclonal antibodies against lymphocytes.
ATG is useful in the setting of refractory or relapsing AAV [16,
73]. The largest cohort described showed 13 partial or complete
disease responses among 15 AAV patients [73]. Thus, ATG may
be considered in non-responders to conventional therapies de-
spite its side effects.
Cytapheresis
Cytapheresis removes specific leucocytes from blood, using spe-
cial columns that precisely deplete these cells [74], and is effec-
tive in AAV [75, 76]. Hasegawa et al. compared cytapheresis plus
low-dose corticosteroid treatment in AAV with kidney involve-
ment against treatment with corticosteroid pulses, and they
found a similar renal recovery rate with lower 1-year mortality
in the cytapheresis group [77]. In a Japanese study, 53 out of 715
AAV patients were treated with cytapheresis. Survival benefit
was observed in those with pulmonary renal syndrome and
higher C-reactive protein (CRP) levels, as well as a faster ANCA
titre decline [78]. Reduction in pro-inflammatory cytokines is
the underlying mechanism for the usefulness of cytapheresis
[79].
Haematopoietic stem cell transplantation
Haematopoietic stem cell transplantation (HSCT) is an emerging
therapy in low-responding patients with autoimmune diseases.
Low mortality and high efficacy have been reported. This ther-
apy alters the disease course and leads to de novo T-cell recon-
stitution. Four refractory AAV patients achieved partial or
complete response after HSCT, without treatment-related mor-
tality, as reported by Daikeler et al. [80].
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Rituximab
Rituximab is an anti-CD20 monoclonal antibody that causes
B-cell depletion and consequently acts on the pathophysiology
of the disease, leading to a dramatic fall in ANCA titre. The
efficacy and safety of this therapy in the induction of disease
remission have been assessed in the RITUXVAS (Rituximab
versus cyclophosphamide in ANCA-associated vasculitis) and
RAVE (Rituximab in ANCA-Associated Vasculitis) trials [81, 82].
Rituximab leads also to T-cell impairment. B-cell depletion
causes a reduction in T-cell-stimulating cytokines produced by
B-cells, and consequently a reduction in peripheral circulating
T-cells [83]. Moreover, a small population of T-cells also express
CD20, constituting a direct target for this therapy [84]. Neél et al.
found that rituximab inhibited CD8þ memory T-cell expansion
in a group of AAV patients, in contrast to conventional immu-
nosuppressive therapy, with no effects on the CD4þ T-cell pop-
ulation [85]. Regarding Tregs, Zhao et al. demonstrated a
repopulation of this subset in patients treated with rituximab
compared with AAV patients treated with conventional ther-
apy, which may also contribute to remission [86].
Abatacept
Abatacept contains the extracellular domain of CTLA-4, which
blocks CD28–B7 interaction, given CTLA-4 affinity for B7. This
co-stimulation blockade inhibits T-cell activation.
Abatacept was administered to 20 patients with non-severe
relapsing AAV, showing a low relapse incidence rate during
follow-up [87]. A randomized controlled trial is currently ongo-
ing, evaluating the efficacy of abatacept in sustaining AAV
relapse in a steroid-free regimen compared with conventional
therapy [88].
Etanercept
TNF-a is involved in the pathogenesis of AAV. The WGET
(Wegener’s Granulomatosis Etanercept Trial) trial evaluated the
efficacy of etanercept in maintaining disease remission.
Etanercept was not useful as maintenance therapy and showed
a worse adverse effect profile [89], particularly neoplasms [90].
Th17 blockade
Antibodies directed against IL-17 and IL-23 (secukinumab and
ustekinumab, respectively) are effectively used in other autoim-
mune conditions such as psoriasis [91], but no current studies
are being conducted in vasculitis yet, despite the existence of a
clear rationale, as described above.
Immunomodulatory therapy
Induction of tolerance by nasal inhalation of MPO at low doses
increases Treg response and attenuates kidney damage in a
murine model of MPO glomerulonephritis. Although no evi-
dence exists in human vasculitis, an immunomodulatory ther-
apy may be effective, based on the high homology between
mouse and human MPO protein [92].
CONCLUSIONS
Characterization of the role of T-cells in AAV has helped to fur-
ther clarify the pathogenesis of AAV. Although multiple inflam-
matory pathways are involved, auto-reactive T-cells are
implicated both in the initiation and in the organization of the
immune response, with population imbalances, as well as func-
tional impairment. T-cells constitute an attractive therapeutic
target for the treatment of AAV.
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